tbuckley/cabot-search huggingface dataset:
SP0101 US FOR ASSESSING LUNG INVOLVEMENT IN RHEUMATIC DISEASES – CLINICAL USE + DEMO
Authors: Andrea Delle Sedie
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Evaluation of interstitial lung disease (ILD) is always difficult (low sensitivity for X-ray and pulmonary function tests or high level of radiation for HRCT): ultrasound (US) has recently shown interesting results on truth, discrimination and feasibility. Due to the thickening of interlobular septa for edema or fibrosis, US beam can interact with those structure and produce artifacts on the screen: B-lines (BL) and pleural line irregularity (PLI). A positive correlation between BL and HRCT has been established both in systemic sclerosis patients and in other patients with ILD; more recently similar results have been published by using PLI as a finding for US assessment in patients. BL has been recently defined by the OMERACT as a vertical hyperechoic reverberation artifact that arise from the pleural line, extend to the bottom of the screen without fading, and move synchronously with lung sliding, while PLI has been defined as a loss of regularity that may be associated with an increase in thickness, focal, diffuse, or nodular. A low number of BLs has been described in healthy subjects but they are generally confined to the posterior and lower part of the thorax. Up to now, many different scanning protocols have been used to assess BL or PLI in patients, providing similar results. <h3>Conclusion:</h3> US lung evaluation is a usefull and feasible imaging technique. <h3>Disclosure of Interests:</h3> Andrea Delle Sedie Speakers bureau: Abbvie, UCB, Celgene, MSD
AB1234 OUTCOME OF EDUCATION WITH REGARD TO INFLUENZA AND PNEUMOCCOCAL VACCINATIONS IN INFLAMMATORY ARTHRITIS PATIENTS ON DMARDS
Authors: Michela Frendo, Ntoriana Tziatzou, Daniel Debattista, Thomas Degiorgio
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Inflammatory arthritis (IA) patients on immunosuppressant disease modifying drugs (DMARDs) are at an increased risk of infections. Influenza and pneumococcal vaccines are recommended as part of the BSR and EULAR guidelines for the clinical management of these patients. Prior to commencing DMARDS, the patients are reviewed by the nurse specialist, who discusses the benefits versus risks of DMARDS, necessary monitoring and recommends the pneumococcal and influenza vaccines. <h3>Objectives:</h3> The aim of this audit is to assess the uptake of the pneumococcal and the influenza vaccine in IA patients prior to starting biologic or synthetic DMARDs as advised by the nurse specialist during the education visit with the patient. <h3>Methods:</h3> The study sample included 139 patients with various types of IA, including rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, who attended the rheumatology nurse education sessions prior to starting DMARDs in a secondary care hospital in 2017. Verbal advice supported by a vaccination leaflet developed in 2016 was given by the rheumatology nurse. Data was compiled by means of a telephone questionnaire. <h3>Results:</h3> One hundred and twenty six (90.6%) participants recalled being given advice on vaccinations. Seventy eight (62%) of these patients received the influenza vaccine. The rest (28%) did not receive the vaccine for various reasons including fear of side effects, fear of developing a worse infection, belief of inefficacy and fear of injections. A significant improvement (p=0.0084) in the influenza vaccination rates was noted since a previous audit in 2016, where following verbal education by a rheumatologist, only 41.4% received the influenza vaccine. A significant improvement in uptake was also noted in the pneumococcal vaccination rates since only 17.2% of the patients received the pneumococcal vaccine in 2016 compared to 62.7% in 2017 (p&lt;0.0001). Various reasons including fear of side effects, belief of inefficacy, fear of injections and financial implications were given by patients who did not receive the pneumococcal vaccine. Overall, 62% of the patients received both vaccines after education given by the rheumatology specialist nurse and receiving the vaccination leaflet. <h3>Conclusion:</h3> This audit showed a significant progress in the uptake of the influenza and pneumococcal vaccinations in patients with inflammatory arthritis following verbal advice by the specialist rheumatology nurse and the introduction of a vaccinations' educational leaflet. <h3> Disclosure of Interests:</h3> None declared
PB1766 ASSESSMENT OF MINIMAL RESIDUAL DISEASE IN ADULT EGYPTIAN ACUTE MYELOID LEUKEMIA PATIENTS
Authors: M.M. Moussa, E. abd elmohsen, N.E. hussein, I.G. mahmoud
Journal: HemaSphere (2019)

Background: The term minimal residual disease (MRD) is used to describe residual disease after suboptimal induction chemotherapy, but at the same time refers to the lowest levels of disease potentially compatible with cure or to molecularly defined relapse after long term remission. This study assesses the minimal residual disease in relation to the outcome in acute myeloid leukemia patients after 6 months of treatment of chemotherapy. Aims: The aim of this study is assessment of measurable minimal residual disease after treatment to identify acute myeloid leukemia patients who are at high risk of poor outcome. Methods: Minimal Residual Disease was measured using Flow cytometry in 30 newly diagnosed a 30 newly diagnosed acute myeloid leukemia (AML) patients. The patients were recruited from clinical hematology department at Ain shams university hospital over the period from May 2017 to November 2018. Results: A total number of 30 acute myeloid leukemia patients were recruited from Ain Shams University hospital, hematology and Oncology Unit outpatient clinic, with age ranging from 18-60 years old (median age 40 years), 14 of them were males representing 46.6% of the total number and 16 were females representing 53.3% of the total number. There was no statistical significance between the age of the studied group and the MRD with P-value 0.147, the sex of the patients doesn’t contribute to the risk stratification with a P-value of 0.200. The number of cases with negative MRD after induction was 13 representing 43.3% of the total number, and was 12 patients after 6 months representing 70.5% of the remitted patients, considering that the cut out value of MRD is 0.1. There was a significant relationship between TLC and MRD, the higher the TLC the more positive the MRD. Positive MRD is associated with higher mortality rates, exhibiting a statistical significance with P-value of 0.005. Summary/Conclusion: We concluded that assessment of minimal residual disease in AML is of great value in determination of prognosis of the disease and its outcome and it is of great value to determine the levels of minimal residual disease (MRD) during the course of therapy and to stratify patient to identify high risk patient and to plan the therapeutic program accordingly.
FRI0498 HIGH SERUM URIC ACID LEVEL IS ASSOCIATED WITH LOWER INCIDENCE OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN: DATA FROM THE KOREAN NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY
Authors: Eun-Jung Park, Yeoung Hee Eun, In-Young Kim, Hyemin Jeong, Jinseok Kim, Hyungjin Kim, Jaejoon Lee
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Osteoporosis is one of the most common morbidities in postmenopausal women. Although serum uric acid (SUA) accounts for about 50% of extracellular antioxidant activity, the role of hyperuricemia in osteoporosis, a condition characterized by high oxidative stress level, has not been investigated in a Nation-wide scale. <h3>Objectives</h3> The aim of this study is to evaluate an association between SUA and incidence of osteoporosis in postmenopausal women. <h3>Methods</h3> Data of postmenopausal women from the 2016 Korean National Health and Nutrition Examination Survey were included and retrospectively analyzed. Weighted prevalence and logistic regression analysis were used to determine the incidence of osteoporosis and the effect of SUA on osteoporosis in postmenopausal women. <h3>Results</h3> One-thousand three-hundred eighty-two (weighted n = 7,064,137) of postmenopausal women were observed. Of these, 401 (29.0%, weighted n = 1,880,586) women developed osteoporosis. Mean age of participants was 63.2 years and mean of SUA was 4.4 mg/dL. The effect of SUA on osteoporosis in postmepausal women was not statistically significant according to univariable logistic regression (OR 0.977, 95% CI 0.855-1.116, <i>p</i> = 0.729). However, SUA was negatively associated with incidence of osteoporosis in postmenopausal women with statistical significance after adjusting for age, obesity, amount of drink, smoking, intake of calcium, rheumatoid arthritis, thyroid diseases, and loss of activity (OR 0.867, 95% CI 0.752-0.999, <i>p</i> = 0.048). <h3>Conclusion</h3> Our data demonstrated that high SUA is associated with lower incidence of osteoporosis in postmenopausal women. This result suggests a protective role of SUA in metabolic bone diseases. <h3>References</h3> [1] Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8:136. [2] Varacallo MA, Fox EJ. Osteoporosis and its complications. Med Clin North Am. 2014;98(4):817-31. [3] Wauquier F, Leotoing L, Coxam V, Guicheux J, Wittrant Y. Oxidative stress in bone remodelling and disease. Trends Mol Med. 2009;15(10):468-77. [4] Lee NK, Choi YG, Baik JY, Han SY, Jeong DW, Bae YS, et al. A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation. Blood. 2005;106(3):852-9. [5] Bai XC, Lu D, Liu AL, Zhang ZM, Li XM, Zou ZP, et al. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast. J Biol Chem. 2005;280(17):17497-506. <h3>Disclosure of Interests</h3> None declared
Evolution of DNA Methylation in Papio Baboons
Authors: Tauras P Vilgalys, Jeffrey Rogers, Clifford J Jolly, None Baboon Genome Analysis, Sayan Mukherjee, Jenny Tung
Journal: Molecular Biology and Evolution (2018)

Abstract Changes in gene regulation have long been thought to play an important role in primate evolution. However, although a number of studies have compared genome-wide gene expression patterns across primate species, fewer have investigated the gene regulatory mechanisms that underlie such patterns, or the relative contribution of drift versus selection. Here, we profiled genome-scale DNA methylation levels in blood samples from five of the six extant species of the baboon genus Papio (4–14 individuals per species). This radiation presents the opportunity to investigate DNA methylation divergence at both shallow and deeper timescales (0.380–1.4 My). In contrast to studies in human populations, but similar to studies in great apes, DNA methylation profiles clearly mirror genetic and geographic structure. Divergence in DNA methylation proceeds fastest in unannotated regions of the genome and slowest in regions of the genome that are likely more constrained at the sequence level (e.g., gene exons). Both heuristic approaches and Ornstein–Uhlenbeck models suggest that DNA methylation levels at a small set of sites have been affected by positive selection, and that this class is enriched in functionally relevant contexts, including promoters, enhancers, and CpG islands. Our results thus indicate that the rate and distribution of DNA methylation changes across the genome largely mirror genetic structure. However, at some CpG sites, DNA methylation levels themselves may have been a target of positive selection, pointing to loci that could be important in connecting sequence variation to fitness-related traits.
THU0547 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA IN PEDIATRIC RHEUMATOLOGY PRACTICE: LARGE SERIES EXPERIENCE OF THE SINGLE CENTER
Authors: Irina Nikishina, Alia Latypova, Maria Kaleda, Svetlana Arsenyeva, Dmitrii Alexseev
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Fibrodysplasia Ossificans Progressiva (FOP), also known as a "second skeleton disease" is extremely rare (1: 2000000) and disabling genetic disorder, caused by mutation of ACVR1 gene, a bone morphogenetic protein receptor. Among medical specialties there are no certain, capable to provide not only diagnostics, but also all medical maintenance (assessment and monitoring of extent of damages, the differentiated drug treatment, rehabilitation, contact with adjacent experts). It would be reasonable if the rheumatologist carried out a role of the main attending physician for the patient with FOP. It seems to be a lot of similarities between rheumatic diseases, especially spondyloarthritis (SpA) and FOP in the pathophysiology, clinical manifestation and the therapy approach. Objectives: to present the single-center experience of the FOP patients and to identify similar symptoms in FOP and rheumatic disease. <h3>Methods</h3> The analysis of the large series of patients with FOP, who observed in the rheumatologic clinic. <h3>Results</h3> Our single center experience includes 26 patients with FOP. All 26 patients (13 male and 13 female) had 3 basic FOP clinical manifestations. In 23 patients molecular-genetic tests were performed and typical mutation (Arginine 206) occurred in 22 cases and one had an extremely rare mutation (Glicine 328). 22 (85%) patients had common for FOP massive heterotopic ossifications. 3 of them had formed heterotopic ossification through the X-ray negative stage to visible changes. Among typical phenotypic stigmas were: great toe malformation; thumbs malformation; peripheral osteochondromas; cervical spine abnormalities. Majority of the cases presented some similarities to SpA manifestations: ankylosis of the apophysial joints and vertebral bodies mostly in cervical spine; X-ray/CT evidence of the sacroiliitis in all patients, who were examined (n=8). Because of severe body deformity or metal details after previous surgery intervention there were no possibility to perform MRI in most patients, but we confirm typical sacroiliitis with extended bone edema on MRI in 3 patients. Recurrent episodes of the large joints synoviitis were present in 5 patients. 4 patients demonstrated gradually formation of great toe ankylosis during the follow-up observation. The involution and decreasing of new FOP nodes associated with non-steroidal anti-inflammatory drug intake and/or glucocorticoids therapy were occurred in all patients. <h3>Conclusion</h3> Appearance of the similarities in FOP and SpA manifestation and the therapy approach could identify FOP as a potential rheumatic disease. Clinical observation of FOP patients could provide the important information for rheumatologist about insufficiently explored process of new bone formation. <h3>Disclosure of Interests</h3> None declared
SP0001 WIN IN OA MANAGEMENT
Authors: Francis Berenbaum
Journal: Annals of the Rheumatic Diseases (2019)

<h3></h3> All recommendations on the management of osteoarthritis (OA), including EULAR, consider that its treatment should include pharmacological and non-pharmacological treatments. In this lecture, the most recent advances in both fields will be addressed. Some of them can change our current practice like recommendations on physical activity or on the choice of analgesics. Moreover, this lecture will highlight some of the drugs and cell therapies in development that could be on the market in the very close years <h3>Disclosure of Interests</h3> None declared
pH‐Triggered Conformational Change of Antp‐Based Drug Delivery Platform for Tumor Treatment with Combined Photothermal Therapy and Chemotherapy
Authors: Peiqing Liang, Mohong Wang, Shixiong Zhang, Jiayu Wang, Chunlei Dai, Changyun Quan
Journal: Advanced Healthcare Materials (2019)

Poor cellular uptake and low therapeutic efficacy of small-molecule antitumor drugs limit the application of drug delivery systems (DDSs) in cancer therapy. A conformational change of the Antp mimetic peptide (AMP) in tumor microenvironments can greatly increase the cellular uptake as well as control drug release from a DDS. In this study, AMP-based nanoparticles (AMP-NPs) conjugated with tyroserleutide (YSL), an immunologically therapeutic tripeptide, are designed to encapsulate doxorubicin (Dox) and indocyanine green (ICG) to improve cellular uptake and cancer therapeutic efficacy by combining chemotherapy with photothermal therapy. In vitro studies verify that AMP-NPs can control the release of Dox and YSL at different pH values. Cell experiments show that AMP-NPs can promote the cellular uptake of Dox, and YSL can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression. In a mouse xenograft model using H22 cells, tumors are ablated when Dox- and ICG-loaded AMP-NPs are injected with the combination of hyperthermia effect induced by near-infrared (NIR) laser irradiation and chemotherapy from Dox and YSL. The pH-, photothermal-, and glutathione-responsive AMP-NPs with a conformational transition strategy can be utilized to synergistically enhance the cancer therapeutic efficacy with few side effects upon NIR laser irradiation.
Erratum. Should Viscous Fiber Supplements Be Considered in Diabetes Control? Results From a Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2019;42:755–766
Authors: Elena Jovanovski, Rana Khayyat, Andreea Zurbau, Allison Komishon, Nourah Mazhar, John L. Sievenpiper, Sonia Blanco Mejia, Hoang Vi Thanh Ho, Dandan Li, Alexandra L. Jenkins, Lea Duvnjak, Vladimir Vuksan
Journal: Diabetes Care (2019)

The authors wish to make a modification in their article as regards a study by Li et al. (2016) to exclude reporting of the short-term, interim effect of β-glucan on glycemic …
SP0112 IMMUNOSUPPRESSION – ONE FITS ALL VS. INDIVIDUALIZED SELECTION?
Authors: Marco Matucci-Cerinic
Journal: Annals of the Rheumatic Diseases (2019)

<h3></h3> Systemic sclerosis (SSc) is an autoimmune disease characterised by skin, vascular and internal organ involvement leading eventually to tissue fibrosis and atrophy. The best control of the disease is usually achieved in the early phase which is characterised by a diffuse tissue inflammation and vasculopathy. of the tissues. In this phase an immunosppressive stragey can in fact lead to disease remission even if some cases may escape control and progress inesorably to fibrosis. Classically, the clinical profile of the patient needs to be achieved. The subset, the disease activity and the main clinical features should be defined in order to have the precise profile of the disease. The knowledge of the clinical conditions may therefore help in deciding the drug and shaping the therapeutic regimen and its intensity. Usually, the use of Cyclophosphamide (CYC) and Micophenolate (MMF) may fit the necessity of the largest part of the SSc population. In practice, CYC may be employed as an induction treatment, eithe rorally or intravenous, while MMF may be used as a maintenance therapy. Both drugs have been demonstrated to be useful in the treatment of SSc either on the cutaneous or on the lung involvement. However, the most severe and refractory cases may be today considered for a hematopietic stem cell transplantation (HSCT). In this case, an individualised selection is performed before a patient can be considered fit to receive this kind of therapeutic regimen. Therefore, the treatment is strictly individualised and only after having a thorough clinical evaluation the patient can be accepted for the systemic conditioning with high doses of CYC for bone marrow ablation. In conclusion, the treatment of SSc is today mainly centered on immunesuppression whose intensity must be decided and individualized according to the disease activity. New innovative targeted drugs are on the horizon in the effort to find the right immunosuppressive and antifibrotic therapeutic approach clinically tailored on the SSc patient. <h3>Disclosure of Interests:</h3> Marco Matucci-Cerinic Grant/research support from: Actelion, MSD, Pfizer, BMS, Chemomab, Sanipedia, Speakers bureau: Actelion, BMS; MSD, Janssen
Atrial Fibrillation Detection With Wearable Devices
Authors: Cameron T. Lambert, Joseph M. Bumgarner, Khaldoun G. Tarakji
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal